Expression of RAD54B in liver hepatocellular carcinoma and its influence on clinical prognosis

doi:10.3969/j.issn.1009-976X.2024.04.004

Abstract

Abstract: Objective To explore the significance of RAD54B expressionin liver hepatocellular carcinoma （LIHC）, and the difference of RAD54B expression level between LIHC and normal tissues, analyze its influence on patient prognosis. Methods Analyze the mRNA expression of RAD54B in LIHC and its impact on survival by using the TCGA online database. By using the human liver cancer tissue microarray （TMA）, evaluate the expression of RAD54B in LIHC by using immunohistochemical staining, and explore the impact of RAD54B on patient prognosis and its correlation with clinical pathological characteristics.Chi-square test was performed according to the correlation between antibody expression and clinical indicators of patients with LIHC, and univariate COX regression analysis and multivariate COX regression analysis were performed to screen out independent prognostic factors. The TCGA database was used to construct the nomogram and prognostic risk score model for RAD54B. Results TCGA database analysis showed that the expression level of RAD54B mRNA in LIHC tissues was higher than that in normal liver tissues. Immunohistochemical staining results also showed that the level of RAD54B protein expressed in LIHC tissue was significantly higher than that in normal liver tissue. The bioinformatics analysis of TCGA database and survival analysis of immunohistochemistry staining showed that the overall survival of the RAD54B high expression group was significantly reduced compared to the low expression group. Moreover, the expression of RAD54B is significantly correlated with multiple clinical features such as tumor size, TNM staging, and tumor grade in LIHC patients. Conclusion RAD54B as a prognostic factor for LIHC, is correlated with the size, stage, and differentiation of the patient's tumor. RAD54B may provide a new therapeutic target for LIHC treatment.

Key words: liver hepatocellular carcinoma, RAD54B, prognosis

摘要： 目的研究RAD54B在肝细胞癌（LIHC）中的表达意义,与其在肝细胞癌和正常组织中的表达差异和对患者预后的影响。方法利用癌症基因组图谱（TCGA）在线数据库分析RAD54B在LIHC中的mRNA表达及其对生存期的影响;使用人肝癌组织芯片（TMA）,利用免疫组织化学染色评估RAD54B在LIHC中的表达,并探讨RAD54B对患者预后的影响及临床病理特征的相关性。结果 TCGA数据库分析表明,LIHC组织中RAD54B mRNA表达水平高于正常肝组织。免疫组化染色也提示LIHC组织表达的RAD54B蛋白水平明显高于正常肝组织。TCGA 数据库生信分析及免疫组化染色的生存分析表明,RAD54B高表达组的总生存期较低表达组显著降低。而且,RAD54B的表达与LIHC患者的肿瘤大小、TNM分期、肿瘤的分级（Grade）等多个临床特征显著相关。结论 RAD54B作为LIHC的预后因子,其表达与患者的肿瘤大小、肿瘤分期及分化程度具有相关性,RAD54B可能为LIHC治疗提供新的治疗靶点。

关键词: 原发性肝细胞癌, RAD54B, 预后

CLC Number:

R657.3

ZHENG Biao, CHEN Xu, QIAN Junlin, XU Baoshi, ZHEN Chaohui, LIANG Rui. Expression of RAD54B in liver hepatocellular carcinoma and its influence on clinical prognosis[J]. Lingnan Modern Clinics In Surgery, 2024, 24(04): 225-230.

郑彪, 陈旭, 钱均霖, 许宝石, 甄潮辉, 梁锐. RAD54B在肝细胞癌中的表达及对临床预后的影响[J]. 岭南现代临床外科, 2024, 24(04): 225-230.

References

[1] Tümen D, Heumann P, Gülow K, et al.Pathogenesis and current treatment strategies of hepatocellularcarcinoma[J]. Biomedicines, 2022, 10(12): 32024
[2] Smith CL, Peterson CL.A conserved Swi2 /Snf2 ATPase motif couples ATP hydrolysis to chromatin remodeling[J]. Mol Cell Biol, 2005, 25(14): 5880-5892.
[3] Sarai N, Kagawa W, Fujikawa N, et al.Biochemical analysis of the N-terminal domain of human RAD54B[J]. Nucleic Acids Res, 2008, 36(17): 5441-5450.
[4] Hiramoto T, Nakanishi T, Sumiyoshi T, et al.Mutations of a novel human RAD54 homologue, RAD54B, in primary cancer.[J] Oncogene, 1999, 18(22): 3422-3426.
[5] 邱世岳. 同源重组修复蛋白RAD54B在肿瘤中的研究进展[J]. 临床与实验病理学杂志, 2020, 36(09): 1070-1072.
[6] Nagai Y, Yamamoto Y, Yasuhara T, et al.High RAD54B expression: an independent predictor of postoperative distant recurrence in colorectal cancer patients[J]. Oncotarget, 2015, 6(25): 21064-21073.
[7] Xu C, Liu D, Mei H, et al.Knockdown of RAD54B expression reduces cell proliferation and induces apoptosis in lung cancer cells[J]. J Int Med Res, 2019, 47(11): 5650-5659.
[8] Yasuhara T, Suzuki T, Katsura M.Rad54B serves as a scaffold in the DNA damage 35 response that limits checkpoint strength[J]. Nat Commun, 2014, (5): 5426.
[9] Zhang Z, Li X, Han Y, et al.RAD54B potentiates tumor growth and predicts poor prognosis of patients with luminal A breast cancer[J]. Biomed Pharmacother, 2019, (118): 109341.
[10] Zhu Y, Zhou C.High miR-139-3p expression predicts a better prognosis for hepatocellular carcinoma: a pooled analysis[J]. J Int Med Res, 2019, 47(1): 383-390.
[11] Feng S, Liu J, Hailiang L, et al. Amplification of RAD54B promotes progression of hepatocellular carcinoma via activating the Wnt/β-catenin signaling[J]. Transl Oncol, 2021 Aug;14(8): 101124.
[12] Cerami E, Gao J, Dogrusoz U, et al.The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data[J]. Cancer Discov, 2012, 2(5): 401-4.
[13] Xu C, Liu D.Knockdown ofRAD54B expression reduces cell proliferation and induces apoptosis in lung cancer cells[J]. J Int Med Res, 2019, 47(11): 5650-5659.
[14] Nagai Y, Yamamoto Y, Yasuhara T, et al.HighRAD54B expression: An independent predictor of postoperativedistant recurrence in colorectal cancer patients[J]. Oncotarget, 2015, 6(25): 21064-21073.
[15] Wang R, Li Y, Chen Y, et al.Inhibition of RAD54B suppresses proliferation and promotes apoptosis in hepatoma cells[J]. Oncol Rep, 2018, 40(3): 1233-1242.
[16] Li Z, Guo Y, Zhou L, et al.Association of a functional RAD52 genetic variant locating in a miRNA binding site with risk of HBV-related hepatocellular carcinoma[J]. Mol Carcinog, 2015, 54: 853-858.
[17] Shao J, Xu Z, Peng X, et al.Gefitinib Synergizes with Irinotecan to Suppress Hepatocellular Carcinoma via Antagonizing Rad51-Mediated DNA-Repair[J]. PLoS One, 2016, 11(1): e0146968.
[18] 原发性肝癌诊疗指南(2024年版)[J].中国普通外科杂志,2024,33(04):475-530.